RARA CRAFT DATABASE for FDA Medical Devices
510(k)K181916

FDA DEVICE FACTS

d-Nav System

Hygieia, Inc

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

AI/ML
DECISION DATEFebruary 4, 2019PRODUCT CODENDC

Indications for use

My Insulin Doser/IDS calculates the next dose of insulin to optimize a diabetic patient’s individual insulin management. The d-Nav® System calculates the next dose of insulin to aid in optimizing insulin management. The d-Nav System contains two user-interactive software elements:

• The patient user interface software is intended for use by adult s with Type 2 diabetes as an aid in optimizing insulin management. It resides on a hand-held device, e.g. cellular phone or enabled glucose meter, and is used to enter glucose event data and receive a recommended insulin dose.

• The HCP user i nterface software tool is intended for use by Health Care Providers (HCPs) to set up the patient so ftware for its intended use. Setup consists of entering the physician-prescribed, patient-specific starting insulin dose instructions (insulin prescription) and sending the information to the patient user software. Insulin instructions include the treatment algorithm (treatment plan), insulin drug, and dose(s). The d-Nav System also contains the d-Nav Get-Dose Library that provides the next insulin dose. The System can receive glucose measurement data entered manually into the patient user software or automatically via the cloud from a linked blood glucose meter. The d-Nav Get-Dose Library Recommend Dose function resides locally on the phone while the d-Nav Get-Dose Library Update Insulin Instruction function may reside locally on the phone or be hosted in the cloud. Configurations are as follows: Model 1: Patient user software resides on a hand-held device and uses manual glucose measurement entry. The Get-Dose Library Update Insulin Instruction function resides locally within the device. Model 2: Patient user software resides on a hand-held device and uses manual glucose measurement entry. The Get-Dose Library Update Insulin Instruction function resides in the cloud. Model 3: Patient user software resides on a hand-held device and uses automated glucose measurement entry. The Get-Dose Library Update Insulin Instruction function resides locally within the device. Model 4: Patient user software resides on a hand-held device and uses automated glucose measurement entry. The Get-Dose Library Update Insulin Instruction function resides in the cloud. Use of the d-Nav System is limited to Health Care Providers who have been trained by Hygieia or a Hygieia trained person on the use of the d-Nav System, including setup of the patient’s Phone App. Hygieia, Inc. Premarket Notification – 510(k) d-Nav System SE Discussion of Intend ed Use Both devices require a prescription from the treating clinician and both are set up by Health Care Providers in a professional setting and used by persons with diabetes in a home setting. The devices are both intended for use by healthcare professionals and their patients with Type 2 diabetes for calculating insulin dose. The intended use of the d-Nav System is similar to that of the predicate, as both are software devices that calculate the next dose of insulin to aid in optimizing insulin management. Both devices calculate the insulin dose based on previous response to aid in optimizing insulin management. The predicate uses a single dose to calculate a dose response. The subject device uses both a single dose to calculate dose reductions and a weekly average based on the relative time point for that insulin dose (i.e. breakfast, or bedtime) to calculate both dose increases and decreases. Neither device is intended to be a substitute for clinical reasoning. Substantial Equivalence Discussion of Technological Characteristics Hygieia has referred to FDA’s document “The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)] - Guidance for Industry and Food and Drug Administration Staff (July 28, 2014)” while drafting this evaluation of substantial equivalence with the predicate device.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: July 28, 2026